Tiziana Life Sciences Identifies New Immune Biomarkers in Multiple Sclerosis Patients Treated with Foralumab
Shots:
- Tiziana identified new immune biomarkers in na-SPMS patients treated with nasal foralumab, using single-cell RNA sequencing of peripheral blood samples taken before treatment & at 3 as well as 6mos. post-administration
- Study showed that after dosing in ongoing ISPPEA (expanded access program; n=10), gene expression changed starting 3mos. incl. modulation of FoxP3 Tregs, CD4+/CD8+ central memory T cells, CD14+/- monocytes, & naïve B cells. This was linked to a decrease in microglial brain inflammation, measured by PET scans in patients
- Foralumab is a fully human anti-CD3 mAb that stimulates T cells after intranasal administration & is under assessment in P-IIa trial in na-SPMS patients
Ref: Tiziana Life Sciences | Image: Tiziana Life Sciences
Related News:- Silexion Therapeutics Reports Preclinical Data for SIL-204 in Combination with 1L Chemotherapies for Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
